Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs.

Molecular cancer therapeutics·2025
Same author

Overdosage Section in US and EU Labeling.

Therapeutic innovation & regulatory science·2024
Same author

Towards controlling the glycoform: a model framework linking extracellular metabolites to antibody glycosylation.

International journal of molecular sciences·2014
Same author

FIBS-enabled noninvasive metabolic profiling.

Journal of visualized experiments : JoVE·2014
Same author

Opportunities for bioprocess monitoring using FRET biosensors.

Biochemical Society transactions·2013
Same author

Inhibition of poly(ADP-ribose) polymerase attenuates acute kidney injury in sodium taurocholate-induced acute pancreatitis in rats.

Pancreas·2012

Related Experiment Video

Updated: May 30, 2026

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

Modulating antibody pharmacokinetics using hydrophilic polymers.

Chen Chen1, Antony Constantinou, Mahendra Deonarain

  • 1Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK.

Expert Opinion on Drug Delivery
|August 23, 2011
PubMed
Summary

Polyethylene glycol (PEG)ylation enhances protein drug delivery by increasing half-life and stability. While PEGylation is established, alternative biodegradable polymers and recombinant methods offer potential advantages for future protein therapeutics.

More Related Videos

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Microwave-assisted Functionalization of Poly(ethylene glycol) and On-resin Peptides for Use in Chain Polymerizations and Hydrogel Formation
15:33

Microwave-assisted Functionalization of Poly(ethylene glycol) and On-resin Peptides for Use in Chain Polymerizations and Hydrogel Formation

Published on: October 29, 2013

Related Experiment Videos

Last Updated: May 30, 2026

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Microwave-assisted Functionalization of Poly(ethylene glycol) and On-resin Peptides for Use in Chain Polymerizations and Hydrogel Formation
15:33

Microwave-assisted Functionalization of Poly(ethylene glycol) and On-resin Peptides for Use in Chain Polymerizations and Hydrogel Formation

Published on: October 29, 2013

Area of Science:

  • Bioconjugation Chemistry
  • Protein Engineering
  • Drug Delivery Systems

Background:

  • Hydrophilic polymers, like polyethylene glycol (PEG), are increasingly used to replace the Fc-domain in binding proteins.
  • PEGylation improves protein drug properties, including extended blood half-life, bioavailability, stability, and reduced immunogenicity.
  • While effective, PEG is non-biodegradable, prompting research into alternative modification strategies.

Purpose of the Study:

  • To review current antibody PEGylation techniques and their effects.
  • To explore non-biological and biological alternatives to PEGylation.
  • To discuss recombinant approaches that may eliminate the need for chemical modification.

Main Methods:

  • Review of existing literature on antibody PEGylation approaches and outcomes.
  • Description of non-biological alternatives, such as N-(2-hydroxypropyl)methacrylamide.
  • Discussion of biological alternatives, including polysialylation and glyco-engineering.
  • Exploration of recombinant protein strategies, such as hydrophilic peptides.

Main Results:

  • PEGylation remains a clinically approved and widely used method for enhancing protein therapeutics.
  • Alternative polymers and recombinant methods show promise for improved properties and biodegradability.
  • Emerging small protein mimics will drive the demand for advanced conjugation technologies.

Conclusions:

  • PEGylation is the current gold standard due to its established track record.
  • Alternative technologies must demonstrate comparable pharmacokinetics and additional benefits like simpler production.
  • A combination of PEGylation and novel approaches will likely shape the future of protein drug development.